Nogitecan
Ovarian Mucinous Cystadenocarcinoma
Explore 5 assets in Ovarian Mucinous Cystadenocarcinoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Gynecologic Oncology Group
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Mucinous Cystadenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nogitecan (this asset) | Gynecologic Oncology Group | P2 | B · 60 |
| Carboplatin | Gynecologic Oncology Group | P3 | BB |
| Capecitabine | National Cancer Institute (NCI) | P3 | BB |
| Nivestim | University of Washington | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P3 | B |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | B |
| Urokinase-Derived Peptide A6 | Gynecologic Oncology Group | P2 | B |
| Sargramostim | University of Washington | P2 | B |
| Belinostat | National Cancer Institute (NCI) | P2 | B |
+13 more in the Ovarian Mucinous Cystadenocarcinoma cohort
Other indications for Nogitecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P3 | BBB · 74 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Non-Small Cell Lung Carcinoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nogitecan in Ovarian Mucinous Cystadenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nogitecan-ovarian-mucinous-cystadenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →